Caris Life Sciences (CAI) awards 13,192-share RSU grant to director Vacirca

Rhea-AI Filing Summary

Vacirca Jeff L reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences director Jeff L. Vacirca received a grant of 13,192 shares of Common Stock on 2026-08-14, reported as an award of restricted stock units that vest under the applicable grant agreement. The award was recorded at $0.00 per share, and his direct holdings increased to 62,863 shares following the grant.

Insider Trade Summary

Net Buyer: 13,192 shares

Net Buy 1 txn

Insider Vacirca Jeff L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	13,192	$0.00	$0.00

Holdings After Transaction: Common Stock — 62,863 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Key Figures

Shares granted: 13,192 shares Holdings after transaction: 62,863 shares Reported price per share: $0.00 per share +1 more

4 metrics

Shares granted 13,192 shares Award of restricted stock units to director on 2026-08-14

Holdings after transaction 62,863 shares Direct Common Stock holdings of Jeff L. Vacirca after award

Reported price per share $0.00 per share Equity award of restricted stock units, non-cash compensation

Equity award transactions 1 transaction Form 4 reports one grant/award acquisition (code A)

Key Terms

restricted stock units, Grant, award, or other acquisition, direct ownership

3 terms

restricted stock units financial

"Represents an award of restricted stock units which vest in accordance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

direct ownership financial

"total_shares_following_transaction ... ownership_type: direct"

FAQ

What insider transaction did Caris Life Sciences (CAI) report for Jeff L. Vacirca?

Caris Life Sciences reported that director Jeff L. Vacirca received a grant of 13,192 shares of Common Stock as an award of restricted stock units, which vest according to the applicable grant agreement.

How many CAI shares does Jeff L. Vacirca hold after this Form 4 transaction?

After the reported award, Jeff L. Vacirca directly holds 62,863 shares of Caris Life Sciences Common Stock, reflecting the addition of 13,192 granted shares to his previously reported holdings.

What was the price per share for Jeff L. Vacirca’s CAI stock award?

The reported price per share for Jeff L. Vacirca’s award was $0.00, consistent with a compensation-related grant of restricted stock units rather than an open-market purchase of Caris Life Sciences shares.

What type of equity did Jeff L. Vacirca receive from Caris Life Sciences (CAI)?

Jeff L. Vacirca received an award of restricted stock units (RSUs) that settle in Caris Life Sciences Common Stock, with vesting to occur in accordance with the applicable grant agreement terms.

Is Jeff L. Vacirca’s CAI Form 4 transaction a market purchase or a grant?

The Form 4 reports a grant/award acquisition, not a market purchase. The transaction code is “A”, indicating an equity award of restricted stock units that vest under a grant agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:41 PM Accepted by SEC EDGAR 08/14/2026 - 05:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vacirca Jeff L

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		13,192(1)	A	$0	62,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)